Abscisic Acid: A Novel Nutraceutical for Glycemic Control by ZOCCHI, ELENA et al.
June 2017 | Volume 4 | Article 241
Review
published: 13 June 2017
doi: 10.3389/fnut.2017.00024
Frontiers in Nutrition | www.frontiersin.org
Edited by: 
Lorraine M. Sordillo, 
Michigan State University, 
United States
Reviewed by: 
Matteo A. Russo, 
Sapienza Università 
di Roma, Italy  
S. Raza Shaikh, 








This article was submitted to 
Nutritional Immunology, 






Zocchi E, Hontecillas R, Leber A, 
Einerhand A, Carbo A, Bruzzone S, 
Tubau-Juni N, Philipson N, 
Zoccoli-Rodriguez V, Sturla L and 
Bassaganya-Riera J (2017) Abscisic 
Acid: A Novel Nutraceutical for 
Glycemic Control. 
Front. Nutr. 4:24. 
doi: 10.3389/fnut.2017.00024
Abscisic Acid: A Novel Nutraceutical 
for Glycemic Control
Elena Zocchi1*, Raquel Hontecillas2,3*, Andrew Leber2, Alexandra Einerhand2,  
Adria Carbo2, Santina Bruzzone1, Nuria Tubau-Juni3, Noah Philipson2,  
Victoria Zoccoli-Rodriguez2, Laura Sturla1 and Josep Bassaganya-Riera2,3
1 Department of Experimental Medicine, Section of Biochemistry and Center of Excellence for Biomedical Research, 
University of Genoa, Genoa, Italy, 2 BioTherapeutics Inc., Blacksburg, VA, United States, 3 Nutritional Immunology and 
Molecular Medicine Laboratory, Biocomplexity Institute of Virginia Tech, Blacksburg, VA, United States
Abscisic acid is naturally present in fruits and vegetables, and it plays an important role in 
managing glucose homeostasis in humans. According to the latest U.S. dietary survey, 
about 92% of the population might have a deficient intake of ABA due to their deficient 
intake of fruits and vegetables. This review summarizes the in vitro, preclinical, mecha-
nistic, and human translational findings obtained over the past 15 years in the study of 
the role of ABA in glycemic control. In 2007, dietary ABA was first reported to ameliorate 
glucose tolerance and obesity-related inflammation in mice. The most recent findings 
regarding the topic of ABA and its proposed receptor lanthionine synthetase C-like 2 in 
glycemic control and their interplay with insulin and glucagon-like peptide-1 suggest a 
major role for ABA in the physiological response to a glucose load in humans. Moreover, 
emerging evidence suggests that the ABA response might be dysfunctional in diabetic 
subjects. Follow on intervention studies in healthy individuals show that low-dose dietary 
ABA administration exerts a beneficial effect on the glycemia and insulinemia profiles 
after oral glucose load. These recent findings showing benefits in humans, together with 
extensive efficacy data in mouse models of diabetes and inflammatory disease, suggest 
the need for reference ABA values and its possible exploitation of the glycemia-lowering 
effects of ABA for preventative purposes. Larger clinical studies on healthy, prediabetic, 
and diabetic subjects are needed to determine whether addressing the widespread 
dietary ABA deficiency improves glucose control in humans.
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iNTRODUCTiON
ABA is a Conserved Signaling Molecule among Species
ABA is a naturally occurring isoprenoid compound that was originally identified in plants in the 
1960s (1). ABA is also present in metazoans, from sponges up to mammals including humans, and so 
it is well conserved. The chemistry and physiology of ABA and its analogs is described by Milborrow 
(2). The naturally occurring enantiomeric form of ABA is (S)-ABA.
Abbreviations: ABA, abscisic acid; cADPR, cyclic ADP-ribose; cAMP, cyclic adenosine monophosphate; GLP-1, glucagon-
like peptide-1; GLUT4, glucose transporter 4; LANCL2, lanthionine synthetase C-like 2; PKA, protein kinase A; TZD, 
thiazolidinedione.
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Plants have evolved various signaling mechanisms enabling 
them to withstand the multiple environmental conditions to 
which they are exposed, including variable water and nutrient 
availability, temperature variations, and excess ultraviolet-B light. 
Most of the plant responses to these abiotic conditions are medi-
ated by abscisic acid. The ABA-signaling pathway is initiated by 
its binding to the specific receptor complex RCARs/PYR1/PYLs, 
leading to inactivation of type 2C protein phosphatases and 
activation of kinases, which mediate ABA-dependent changes in 
metabolism, gene expression, and ion channel activity (3, 4).
Interestingly, ABA plays essentially the same role in lower 
Metazoa (sponges and hydroids), where it mediates the responses 
of these sessile marine organisms to variations in water tem-
perature and light. In sponges, the oldest Metazoa, their evolution 
dating back to 600 million years, temperature-signaling occurs 
via ABA (5). In Axinella polypoides, an increase of the water tem-
perature results in an increased ABA synthesis and in the ABA-
mediated stimulation of water filtration and oxygen consumption 
(6). Hydroids follow sponges in the evolutionary tree, having 
sensory, nerve, muscle and epithelial cells, a digestive cavity, and 
a rudimentary nervous system, but share with sponges a sessile 
lifestyle. In Eudendrium racemosum, light stimulates endogenous 
ABA synthesis and ABA stimulates stem cell-mediated tissue 
regeneration (7).
ABA Origin and Role in Mammals
In the human body, ABA naturally originates from dietary 
sources and endogenous production through the carotenoid 
biogenesis pathway. ABA was first described in the brain of 
pigs and rats (8). The fact that animals fed a synthetic, ABA-
free diet had ABA levels even higher than those of controls fed 
a vegetable diet was taken as an indirect proof that ABA was 
endogenously produced. To this point, a more recent observa-
tion allows the conclusion that ABA is indeed an endogenously 
produced signaling molecule: plasma ABA (ABAp) levels 
increase significantly in healthy humans after an (ABA-free) 
glucose load (9). On the one hand, this observation points to 
ABA as being endogenously synthesized; plus it suggests a role 
for ABA in the physiological response to glucose intake, a role 
until then shared by insulin and by the incretin glucagon-like 
peptide-1 (GLP-1).
Several in  vitro observations support the conclusion that 
ABA is indeed endogenously produced by human and murine 
cells: granulocytes (10), monocytes and macrophages (11, 12), 
insulin-releasing cells (13), mesenchymal stem cells (MSCs) (14), 
hemopoietic progenitors (HP) (15), adipocytes (9), keratinocytes 
(16), and fibroblasts (17), all have been shown to produce and 
release ABA when exposed to cell-specific stimuli. The cell-
specific functional effects activated by ABA in these cell types 
are in line with a conserved role of ABA as a signal relating cell 
response to changing environmental conditions. The fact that 
several different cell types can produce ABA implies that ABAp 
may derive from multiple sources. Markedly reduced ABAp levels 
were measured in patients with type 1 diabetes as compared 
with healthy individuals of similar age and body mass index 
(9), suggesting that β-pancreatic cells may be a relevant source 
of ABA. High glucose concentrations can stimulate ABA release 
from human adipose tissue biopsies in vitro (9) and the fact that 
adipose tissue accounts for a substantial amount of body weight, 
even in non-obese subjects, may make it another significant 
source of ABAp, in addition to pancreatic β-cells.
Conservation of ABA-Signaling Pathway 
Hallmarks from Plants to Lower Metazoa 
and Mammals: G-Protein-Coupled 
Receptor, Protein Kinase A (PKA),  
cADPR, and Ca2+
One of the chief functions of ABA in plants is to reduce guard cell 
turgor, thereby contributing to the conservation of water during 
periods of drought. This functional response triggered by ABA is 
mediated by an increase of the cytoplasmic Ca2+ concentration 
( )Cacyt
2+  in guard cells, induced by the intracellular Ca2+-mobilizing 
second messenger cyclic ADP-ribose (cADPR) (18, 19). cADPR 
is produced from NAD+ by ADP-ribosyl cyclases (ADPRCs), 
enzymes with an ancient evolutionary origin, being ubiquitously 
expressed from plants to lower and higher Metazoa (20).
Intriguingly, the signaling pathway downstream of ABA 
stimulating water filtration in sponges and tissue regeneration in 
hydroids shares with the plant ABA-mediated stomatal closure the 
same ADPRC-generated second messenger, cADPR (6, 7). ABA 
has been reported to activate the cyclase activity of Arabidopsis 
ADPRC, in the absence of protein synthesis, although the 
mechanism of activation was not elucidated (21). In Eudendrium 
and in Axinella, activation by ABA of the ADPRC occurs via a 
PKA-dependent phosphorylation. Indeed, the signaling pathway 
downstream of ABA in Axinella and in Eudendrium is similar 
and involves the sequential activation of PKA, phosphorylation 
and activation of ADPRC, cADPR overproduction, and increase 
of Cacyt
2+ (5, 7).
The signaling pathway downstream of ABA in human 
granulocytes is strikingly similar to the one unveiled in lower 
Metazoa, and it involves an ADPRC (CD38) and its product 
cADPR (Figure  1). In addition to activating adenylate cyclase 
(AC), ABA also activates phospholipase C (PLC), with the con-
sequent overproduction of inositol triphosphate (IP3); thus, the 
increase of Cacyt
2+  triggered by ABA in granulocytes is mediated 
by both cADPR and IP3 (Figure 1). The G-protein coupled to the 
ABA receptor was identified as Gi by its sensitivity to pertussis 
toxin (PTX) (10). The mechanism through which Gi mediates 
the activation of both PLC and AC was elucidated by means of 
transfection experiments, performed on human granulocytes 
with a chimeric G-protein, resulting from the fusion of Gαi with 
the last five aminoacids of Gαq (Gαq/i), and with transducin (αt), 
a scavenger of βγ subunits. Overexpression of Gαq/i increases the 
contribution of IP3 to the Cacyt
2+ rise induced by ABA and results 
in a fast and transient Cacyt
2+ increase, that becomes evident when 
the contribution of cADPR to the Cacyt
2+  rise is prevented by the 
cADPR antagonist 8Br-cADPR (22). Overexpression of αt damp-
ens the ABA-induced Cacyt
2+ increase, demonstrating that the βγ 
subunits of Gi are responsible for the activation of both PLC and 
AC (22). A role for both cADPR and IP3 in the ABA-triggered 
increase of Cacyt
2+ has been reported in granulocytes (10) and in 
monocytes (12).
FiGURe 1 | ABA signaling in human granulocytes. The interaction of ABA 
with a G-protein-coupled plasmamembrane receptor triggers: (i) activation of 
phospholipase C (PLC), overproduction of inositol triphosphate (IP3), and 
stimulation of a PKC-dependent adenylate cyclase (AC); (ii) activation of AC, 
overproduction of cAMP, protein kinase A (PKA)-mediated stimulation of 
ADP-ribosyl cyclase, and increase of [cADPR]i. Downstream of cyclic 
ADP-ribose (cADPR), two mechanisms (dotted lines) might cooperate to 
induce the observed increase of the [Ca2+]i: extracellular Ca2+ influx through 
store-operated Ca2+ entry (a), or, direct gating of a plasmamembrane Ca2+ 
channel by cADPR (b). Site-specific inhibitors of the ABA-signaling pathway 
are indicated in red. PTX, pertussis toxin; U73122, PLC inhibitor; 
xestospongin, IP3-specific Ca2+-channel blocker; I-PKA and I-PKC, PKA- and 
PKC-specific myristoylated (peptide inhibitors); 8-Br-cADPR, specific cADPR 
antagonist; Ry, Ryanodine (cADPR-specific Ca2+-channel blocker). The 
increased [Ca2+]i levels stimulate functional responses: phagocytosis, release 
of ROS and NO, chemokinesis, and chemotaxis to ABA.
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Conservation of the ABA-signaling pathway sequentially 
involv ing AC, cAMP, PKA-dependent ADPRC activation, cADPR 
overproduction, and Cacyt
2+ increase from sponges to lower and 
higher Metazoa points to its presence at a very early stage of 
evolution, in a precursor common to plants and animals. This 
may suggest an evolutionarily conserved role of ABA in adapta-
tion to environmental stresses that has yet to be fully elucidated 
in humans.
The Mammalian ABA Receptor: 
Lanthionine Synthetase C-Like 2 (LANCL2)
The Arabidopsis membrane-bound ABA receptor GCR2 shares a 
high amino acid identity with the mammalian peptide-modifying 
lanthionine synthetase C-like (LANCL) protein family (23), and 
the LANCL protein family in turn shows structural similarities 
with the prokaryotic lanthionine synthetase component C pro-
teins (24) involved in the synthesis of lanthionine-containing 
antimicrobial peptides known as lantibiotics (25) such as nisin, 
which are used to prevent bacterial growth in foods. However, 
lantibiotics are not produced in animals; thus, mammalian 
LANCL proteins must have a different function than prokary-
otic LanC proteins. The human genome contains three LANCL 
genes, LANCL1, LANCL2, and LANCL3, on chromosomes 2, 7, 
and the X chromosome, respectively (26, 27). In human epi-
thelial cells overexpressing LANCL1 or LANCL2 fused to the 
green fluorescent protein (LANCL1-GFP and LANCL2-GFP), 
LANCL1-GFP is mainly found in the cytosol and in the nucleus, 
whereas LANCL2-GFP is associated with the plasmamembrane 
through N-terminal myristoylation (28). Recently, it has been 
demonstrated that the demyristoylation of LANCL2 by chemical 
or genetic means triggers its nuclear translocation. The nuclear 
enrichment of native LANCL2 was also induced by ABA treat-
ment, suggesting that human LANCL2 is a non-transmembrane 
G-protein-coupled receptor susceptible to hormone-induced 
nuclear translocation (29).
Several lines of evidence support the conclusion that LANCL2 
is a mammalian receptor for ABA. Sturla et al. (22) showed that 
LANCL2 was necessary for ABA binding and signaling in four dif-
ferent cell types (granulocytes, HeLa cells, and RIN-m and INS-1 
cells) from two mammalian species: (i) silencing of LANCL2 
abrogated the ABA-induced increase of the Cacyt
2+ and of cAMP 
in human granulocytes and also prevented the ABA-triggered 
functional response in these cells; (ii) LANCL2 overexpression 
conversely potentiated the Cacyt
2+ increase induced by ABA in 
granulocytes and conferred ABA responsiveness in terms of Cacyt
2+ 
and of cAMP increase to CD38+ HeLa; and finally, LANCL2 
silencing abrogated the ABA-induced biochemical (increase of 
the [Ca2+]i and of the [cAMP]i) and functional (insulin release) 
responses in two different rat insulinoma cell lines. In silico and 
in  vitro studies on the recombinant protein confirmed direct 
ABA binding to human LANCL2 (see ABA Improves Glucose 
Tolerance in db/db Mice Fed a High-Fat Diet).
ABA Regulates Glucose Homeostasis  
in Mammals
Two groups independently hypothesized and experimentally 
validated the role of ABA in regulating glucose metabolism. 
Zocchi and colleagues followed an evolutionary reasoning: in 
plants, ABA lies at the crossroad between physical, nutrient, 
and parasitic stress responses. Its conservation in lower Metazoa 
suggested that it might have similar functions in higher Metazoa: 
indeed, ABA production occurs in human granulocytes (our 
first line of defense against pathogens) stimulated with physi-
cal or chemical stimuli and that ABA activates their defensive 
functions (10). That acute physical stress induces hyperglycemia 
and that the second messengers involved in ABA signaling in 
granulocytes, cAMP and cADPR, played a role in the signaling 
leading to glucose-induced insulin secretion (30, 31) suggested to 
explore the possible role of ABA in the arguably most important 
aspect of mammalian nutrient disposal, i.e., insulin release (13).
Bassaganya-Riera and colleagues were drawn to the study of 
the effect of ABA on mammalian glucose homeostasis based upon 
the structural similarities between ABA and the thiazolidinedione 
(TZD) class of insulin-sensitizing antidiabetic drugs, which bind 
to the ligand-binding domain of the transcription factor PPARγ 
and activate the transcription of several genes involved in glucose 
and lipid metabolism. They provided the first evidence in  vivo 
that ABA exerts glucose-normalizing effects when administered 
to genetically obese db/db mice fed a high-fat diet (32) and to mice 
TABLe 1 | Concentration of ABA in various foodstuffs.
Concentration of ABA in various fruits and vegetables




















*Fruits and vegetables are categorized according to Rehm et al. Vegetables including 
legumes, tomato, and potato.
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with diet-induced obesity (33). Moreover, ABA was shown to 
have similar efficacy to that of TZDs in mouse models of diabetes 
(32). However, ABA was shown to bind LANCL2 and to act inde-
pendently of PPARγ (34). The next section will describe in more 
detail the in vitro and in vivo evidence accumulated until now, 
which confirms and expands our view of ABA as an endogenous 
regulator of glucose disposal in mammals and it highlights the 
fact that ABA is naturally present in our diet thereby providing a 
natural way to balance glucose levels in healthy individuals and 
manage glycemic control in prediabetic, diabetic, and metabolic 
syndrome patients.
ABA: A DieTARY COMPOUND PReSeNT 
iN FRUiTS AND veGeTABLeS
Many countries, including the United States, have a deficient 
intake of fruits and vegetables. On a country-wide scale, this 
results in a broad 1.5- to 2-fold reduction in consumption of 
phytochemicals (35). When individuals who meet fruit and 
vegetable recommendations are compared with those who do 
not, notable reductions in carotenoids (twofold), flavonones 
(threefold), and ellagic acid (fivefold) occur (36). These magni-
tudes of deficiencies have been linked to increased risk for the 
development of cardiovascular disease, metabolic disease, and 
cancer (37, 38).
Specifically, ABA is present in a variety of fruits and vegeta-
bles as shown in Table 1. The concentration varies depending on 
the type of fruit or vegetable but on average the concentration 
of ABA is 0.29/mg/kg wet weight of vegetable and 0.62 mg/kg 
of wet weight of fruit. According to the latest published dietary 
survey data from 2009 to 2012 (39), US adults aged 20 years or 
older consumed on average 1.05  servings/day of whole fruits 
and fruit juices (=  189  g/day) and 1.74 servings of vegetables 
per day including legumes and potatoes (229 g/day). Based on 
averages, a U.S. citizen of 20  years and older would consume 
189 × 0.62 = 117.2 µg of ABA per day derived from fruits and 
229  ×  0.29  =  66.4  µg of ABA per day derived from vegeta-
bles. Thus, a US adult would consume an average of 184 µg of 
ABA per day derived from the 2.79  servings/day of fruits and 
vegetables.
The current recommendation is to eat ≥4.5  servings/day, 
which would lead to ≥297 μg of ABA per day in an ideal situation, 
but only 8% of the US adult population is meeting the dietary 
recommendations for fruits and vegetables of American Heart 
Association 2020 Strategic Goals (39). This means that 92% of the 
population is receiving an ABA-deficient diet according to these 
recommendations. It remains unclear what the ABA deficiency 
means in terms of long-term health effects, but it is tempting to 
speculate that the ABA deficiency might be a risk factor involved 
in the onset of diabetes and cardiovascular disease.
In a study designed to assess the effects of phytochemicals 
on health, an increase of combined fruit and vegetable intake by 
480  g/day tripled the amount systemically available ABA after 
6 weeks, identified ABA as one of three novel biomarkers (along 
with cyclohexadienecarboxylic acid and cyclohexanecarboxylic 
acid) and strongly correlated with decreased CVD risk biomark-
ers in a human trial (52). While a dietary adjustment of this mag-
nitude may be unrealistic in the general population, a standard 
diet, with insufficient fruit and vegetable intake, clearly presents 
suboptimal ABA concentrations throughout the body. Currently, 
insufficient data on the necessity of phytochemical intake and 
the complexity of interactions among the 8,000 identified dietary 
bioactive compounds limit the ability to assign a recommended 
daily intake of ABA and similar compounds (53). However, by 
elucidating specific effects of its deficiency and benefits of its sup-
plementation, ABA can become an accepted nutritional quantity 
like similar compounds, lutein and zeaxanthin with retinal health, 
for certain medical disorders associated with altered glucose 
metabolism and homeostasis.
IN VITRO eFFeCTS OF ABA ON GLUCOSe 
AND LiPiD MeTABOLiSM
ABA Stimulates insulin Release from 
Pancreatic β-Cells and GLP-1 Release 
from enteroendocrine Cells
High glucose concentrations stimulate production and release of 
ABA from rodent insulinoma cells and from human pancreatic 
β-cells (13). Nanomolar ABA in turn stimulates glucose- 
independent (i.e., in the absence of glucose) and potentiates 
glucose-dependent (i.e., in the presence of either low or high glu-
cose) insulin release (13). The signaling pathway of ABA in β-cells 
involves its receptor LANCL2 (22), and the sequential activation 
of PTX-sensitive Gi, AC, cAMP production, PKA-mediated 
phosphorylation and activation of the ADPRC CD38, followed 
by accumulation of cADPR (13).
Oral glucose load stimulates insulin release from pancreatic 
β-cells principally via the incretin GLP-1, which is believed to 
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account for up to 70% of glucose-stimulated insulin release (54). 
GLP-1 is produced and released into the blood by enteroendo-
crine cells (L cells) in response to high glucose concentrations in 
the gut. ABA induces glucose-independent GLP-1 release in the 
human L cell line hNCI-H716 through a cAMP/PKA-dependent 
mechanism and also enhances GLP-1 transcription (55). An 
increase of plasma GLP-1 (GLP-1p) is observed also in  vivo, 
upon oral ABA administration in fasted rats (55). Interestingly, 
GLP-1 stimulates ABA release from an insulinoma cell line and 
from human islets, approximately 10- and 2-fold in low and high 
glucose, respectively (9). Altogether, these results suggest the 
existence of a positive feedback mechanism between ABA and 
GLP-1 activated by hyperglycemia, whereby ABA stimulates 
GLP-1 production by L cells and GLP-1 stimulates ABA release 
from β-cells.
The increases of the GLP-1 and ABA plasma concentrations 
that normally follow oral glucose intake are impaired in type 2 
diabetes (T2D) (56, 57), further supporting the hypothesis of a 
mutual regulation between these molecules. Besides stimulating 
insulin release, GLP-1 has several beneficial effects on the cardio-
vascular system, including stimulation of cardiomyocyte glucose 
uptake in  vitro and prevention of ischemic-reperfusion injury 
and improvement of myocardial performance in vivo [reviewed 
by Sarraju et al. (58)]. Thus, understanding the molecular cross 
talk between ABA and GLP-1 may shed new light on the physiol-
ogy as well as the dysfunction of GLP-1-mediated cardiometa-
bolic protection. In this respect, ABA administration improved 
atherosclerosis-induced hypertension, inflammatory immune 
cell recruitment into the aortic root wall, increased plasma 
triglyceride (TG) and non-esterified fatty acid concentrations, 
and upregulated aortic eNOS expression in ApoE−/− mice (59), 
suggesting that ABA elicits a local antiatherogenic effect in the 
arterial wall of mice and supports its cardiometabolic protective 
role.
ABA Stimulates Glucose Uptake in Rodent 
Adipocytes and Myoblasts
ABA at nanomolar concentrations stimulates glucose uptake by 
differentiated murine adipocytes and by rat myoblasts in  vitro, 
to a similar extent as insulin at the same concentration (9). ABA 
increases glucose transporter 4 (GLUT4) translocation to the 
plasmamembrane in both cell types (9) and stimulates the Ser 
phosphorylation of Akt similarly to insulin (9).
Insulin-independent stimulation of GLUT4 translocation by 
ABA in adipocytes is particularly relevant to the glycemia-lowering 
effect of ABA. Mice with the adipose tissue-specific ablation of 
GLUT4, but normal GLUT4 expression in muscle, are insulin 
resistant and have an increased risk of developing overt diabetes 
(60); adipose tissue-specific GLUT4 KO mice are insulin resistant 
also in liver and muscle (61). Overexpression of GLUT4 in the 
adipose tissue can prevent diabetes in mice defective for muscle 
GLUT4 expression (61). Of note, LANCL2 facilitates phospho-
rylation of Akt by mTORC2 via direct physical interactions with 
both the kinase and the substrate (62). The active mTORC2 causes 
translocation of GLUT4 to the plasma membrane and glucose 
uptake in liver cells (63). Bassaganya-Riera et al. published for the 
first time that ABA treatment prevents LPS-induced downregula-
tion of Glut4 in spleens of mice (34).
ABA AMeLiORATeS GLUCOSe 
TOLeRANCe AND ADiPOSe  
TiSSUe iNFLAMMATiON
ABA improves Glucose Tolerance  
in db/db Mice Fed a High-Fat Diet
Bassaganya-Riera and colleagues demonstrated for the first time 
that ABA improves glucose tolerance in genetically obese db/db 
mice fed a high-fat diet and to mice with diet-induced obesity 
(32, 33). In another study, we demonstrated that ABA performs 
within 98% similarity to the market drug, Avandia, a PPARγ 
agonist. However, as opposed to TZDs, ABA does not bind to 
PPARγ (34). Of note, treatment with ABA helped reduce inflam-
matory markers in the adipose tissue. Specifically, treatment 
with ABA downregulated monocyte chemoattractant protein-1 
(MCP-1) expression and the infiltration of pro-inflammatory 
F4/80+CD11b+ macrophages in the stromal vascular fraction of 
adipose tissue (34). Insulin has been shown to be less effective 
in improving glucose tolerance in an inflamed environment due 
to insulin resistance caused by inflammatory cytokines (64); 
however, the role of adipose tissue inflammation as a driver of 
insulin resistance is still debated. Furthermore, dietary ABA 
supplementation significantly reduced fasting insulin levels 
(65). While the benefits of ABA on glucose tolerance are clear, 
additional research into the impact and mechanisms of ABA in 
insulin resistance will enhance the functional knowledge on the 
actions of ABA in glucose metabolism.
Microgram Amounts of ABA improves 
Glucose Tolerance in Rats and in Humans 
without increasing insulinemia
Despite the strong evidence demonstrating that ABA can 
stimulate insulin release from pancreatic β-cells in  vitro (13), 
subsequent in vivo studies revealed that low-dose ABA improves 
glucose tolerance without increasing insulinemia. Rats and 
healthy humans undergoing an oral glucose tolerance test 
(OGTT) and treated with ABA, at a dose comprised between 0.5 
and 1 μg/kg body weight, both show an improved glycemic profile 
and lower insulin levels compared with untreated controls (40). 
This unexpected result may have several, not necessarily mutually 
exclusive, reasons: (i) stimulation of glucose transport in GLUT4-
expressing cells by ABA may precede in time and/or exceed 
in extent the stimulation of insulin release; (ii) GLUT4-expressing 
cells may be more sensitive to the effect of ABA than β-pancreatic 
cells in vivo. In fact, the dose of ABA appears to be relevant for 
its effect on β-cells in vivo: at 50 mg/kg, oral ABA alone (without 
glucose) increases insulinemia and reduces glycemia in rats (55). 
There is growing consensus within the scientific community that 
the prolonged stimulation of insulin release from β-cells under 
conditions of chronic hyperglycemia contributes to their eventual 
demise (66). For this reason, antidiabetic drugs capable of lower-
ing glycemia without increasing insulinemia are highly desirable.
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ABA increases GLP-1p in Fasted Rats
Besides lowering glycemia and increasing insulin release (only 
when administered at the high concentration of 50 mg/kg), oral 
ABA determines the increase of GLP-1p, this effect having been 
tested only at high ABA concentration (55). The ABA-induced 
GLP-1p increase was measured both in the peripheral blood of 
rats pretreated with sitagliptin (an inhibitor of GLP-1 degrad-
ing enzymes), and in blood withdrawn from the portal vein of 
rats not pretreated with sitagliptin, clearly indicating that ABA 
stimulates also in  vivo the release of GLP-1 from enteroendo-
crine cells, as it was demonstrated in an in  vitro system. The 
increase in GLP-1p preceded the insulin increase (peaks at 20 
and 40 min, respectively); thus, a positive feedback loop might 
exists between ABA increasing GLP-1 (55), which in turn deter-
mines a further release of ABA from β-pancreatic cells (9), which 
potentiate insulin release (13). The effect of low concentrations 
of ABA on the in vivo GLP-1 release remains to be determined. 
Given that a low ABA concentration failed to induce an increase 
in insulinemia, despite its glycemia-lowering effect (40), the 
physiological relevance of the depicted loop at low, endogenous, 
ABA concentration is negligible. It remains unknown whether 
other cell types are able to respond to ABA by releasing GLP-1, 
and whether ABA can stimulate GLP-1 secretion also acting as a 
hormonal stimulus on the vascular side of L-cells, as it happens 
for glucose (67).
Currently, T2D treatments aimed at inhibiting GLP-1-
degrading enzymes (DPP4) or using GLP-1 mimetics are avail-
able (68). The fact that ABA stimulates GLP-1 release accounts 
for considering ABA as a new possible strategy to impact on the 
GLP-1 axis in T2D, alone or in combination with DPP4 inhibitor.
ABA Reduces Adipose Tissue 
inflammation
Obesity and diabetes are characterized by a low-grade systemic 
chronic inflammation and insulin resistance. Hypertrophic adi-
pocytes are insulin resistant and secrete more free fatty acids and 
TGs than they take up, leading to lipid deposition in peripheral 
tissues such as the liver and skeletal muscle. These cells also pro-
duce chemokines, such as MCP-1, which promote macrophage 
infiltration into the white adipose tissue. Bassaganya-Riera’s 
team demonstrated that ABA treatment improves insulin sen-
sitivity, decreases adipocyte hypertrophy, reduces macrophage 
infiltration into the white adipose tissue, and downregulates the 
levels of tumor necrosis alpha (TNFα) and MCP-1 in obese mice 
(32, 33). Later studies demonstrated that ABA, together with 
rosiglitazone, downregulates not only F4/80+CD11b+ pro-inflam-
matory macrophages in white adipose tissue (32), but also levels 
of MCP-1 (59). Interestingly, the downregulation of pro-inflam-
matory markers in ABA-treated mice could be explained by other 
findings, including the observation of upregulation of regulatory 
T (Treg) cells, together with a downregulation of blood CD11b+ 
CCR2+ (the ligand of MCP-1) monocytes (65). Furthermore, 
data demonstrated that with the increase in CD4+ T cells there 
was a corresponding decrease in the percentages of CD8+ T cells 
in MLN following dietary ABA supplementation. Additionally, 
MLN CD4+IL-10+ T  cells and blood CD4+CD25+Foxp3+ Treg 
cells and CD8+IL-10+ T cells were significantly increased in ABA-
fed mice. These results together support the hypothesis that ABA 
reduces obesity-related systemic inflammation, especially in the 
adipose compartment.
The abovementioned findings suggested that the beneficial 
effects of ABA on glucose tolerance were mediated, in part, by 
its anti-inflammatory actions. Mechanistically, the reduction in 
adipocyte hypertrophy can prevent the hypertrophic adipocyte-
induced hypoxia within adipose tissue. HIF1α expression was 
identified to be downregulated by ABA treatment (34). Further, 
expression of HIF-inducible and -interacting genes, such as 
TLR4, JUN, and CDKN1A, were also identified to be downregu-
lated by ABA treatment in splenocytes. Treatment with ABA also 
decreased TLR4 levels in blood and MLN (34). Examination 
of the HIF1α pathway in more detail may unveil additional 
mechanisms of ABA-mediated downregulation of adipose tissue 
inflammation.
impaired Ability to increase ABAp after 
Glucose Load in T2D and Gestational 
Diabetes (GDM)
The increase of ABAp that occurs in healthy subjects after an 
oral glucose load (ABA response) (9) is impaired in patients 
with T2D and in women with GDM (56). GDM is a “reversible” 
diabetic condition that reverts to a normal glucose tolerant state 
after childbirth. Pointedly, normalization of glucose tolerance 
after childbirth was paralleled by restoration of both the ABAp 
response to oral glucose and normal fasting ABAp levels. Thus, 
impairment of the response of ABAp to hyperglycemia might be 
a commonality between T2D and GDM subjects, suggesting an 
important role for ABAp in maintaining normal glucose toler-
ance. Zocchi and colleagues also compared fasting ABAp before 
and after biliopancreatic diversion (BPD) in obese, but not dia-
betic subjects, and in obese T2D patients, in which BPD resulted 
in the resolution of diabetes. Compared to pre-BPD values, 
basal ABAp significantly increased 1  month after BPD in T2D 
as well as in NGT subjects, in parallel with a reduction of fasting 
plasma glucose, suggesting a beneficial effect of elevated ABAp 
on glycemic control (56). An intriguing hypothesis to explain the 
increase of ABAp after BPD is the stimulation of enteroendocrine 
cells by excess non-absorbed nutrients, resulting in an increased 
release of GLP-1 (69, 70), in turn stimulating ABA secretion from 
β-pancreatic cells.
The higher mean value and wider distribution of the fasting 
ABAp in the T2D subjects compared to the NGT controls (56) 
may reflect a pleiotropy of ABA-related dysfunctions in T2D, 
such as: (i) resistance to the glycemia-lowering effect of ABA, 
causing higher than normal basal ABAp levels, or, (ii) impair-
ment of the molecular mechanisms regulating the increase of 
ABAp in response to hyperglycemia, causing ABAp levels to be 
in the normal range despite hyperglycemia. As opposed to what 
observed in T2D subjects, the fasting ABAp of the GDM subjects 
was consistently lower compared to the NGT controls, suggesting 
that insufficient ABA release in response to hyperglycemia may 
be the common mechanism of pathogenesis underlying ABA 
dysfunction in GDM. The fact that ABAp and its response to 
FiGURe 2 | Model structure of lanthionine synthetase C-like 2 (LANCL2) and putative ABA-binding site. (A) Chemical structure of abscisic acid (76).  
(B) Representative binding modes of the most stable docked orientation of ABA (shown in pink) with LANCL2. The amino acid residues surrounding ABA are 
indicated. (C) Surface plasmon resonance sensograms for the binding of varying concentrations of ABA (1, 3, 6, and 12 µM) to immobilized LANCL2. (D) Plot of 
maximal resonance unit versus concentration of ABA. Steady-state dissociation constant was calculated to be 2.252 µM utilizing a 1:1 binding model. Binding data 
first shown by Lu et al. (72).
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hyperglycemia are abnormal in T2D and GDM suggests a role 
for this dysregulation in the pathogenesis of these conditions.
LANCL2 SiGNALiNG PATHwAY
ABA Binding by LANCL2: In Silico  
and In Vitro evidence
Direct evidence of specific and saturable ABA binding to 
recombinant, purified LANCL2 was obtained with two dif-
ferent LANCL2 recombinant proteins, a fusion protein with 
glutathione-S-transferase (LANCL2-GST) and LANCL2 cleaved 
from its GST tag, and through several different experimental 
approaches: binding with [3H]-ABA, scintillation proximity 
assays on immobilized LANCL2, dot blot experiments with 
biotinylated ABA (bio-ABA), and affinity chromatography of 
LANCL2 on immobilized ABA (71).
The relatively high Kd value for ABA of recombinant LANCL2 
could be attributed to imperfect protein folding, as suggested by 
its fast precipitation after tag cleavage or to the requirement of 
posttranslational modifications to enhance its ABA-binding 
activity. Indeed, native LANCL2 is N-terminally myristoylated 
and interacts with membrane phosphatidylinositol phosphate(s), 
both modifications being required for its membrane association 
(28). Both ABA enantiomers, (S)- and (R)-ABA, completely dis-
placed binding of (R,S)-[3H]ABA to LANCL2-GST, in agreement 
with the fact that both (S)- and (R)-ABA are biologically active 
on ABA-sensitive cells.
Parallel in  silico studies, performed on a model structure 
of LANCL2, revealed a potential ABA-binding domain on 
LANCL2. This modeling prediction was validated experimen-
tally using surface plasmon resonance (Figure 2) (72). Using that 
model, structure-based virtual screening was performed using 
compounds from NCI (National Cancer Institute) Diversity 
Set II, ChemBridge, ZINC natural products, and FDA-approved 
drugs databases. Lu et  al. (73) identified several potential 
lig ands using molecular docking. In order to validate the anti-
inflammatory efficacy of the top ranked compound (NSC61610) 
in the NCI Diversity Set II, a series of in vitro and preclinical 
efficacy studies were performed in mice with inflammatory 
bowel disease (IBD). The results in vivo demonstrated that the 
lead compound, NSC61610, engaged LANCL2 in an AC/cAMP-
dependent manner in vitro and ameliorated experimental IBD 
by downmodulating colonic inflammatory gene expression and 
favoring Treg cell responses (73). New derivatives and analogs of 
ABA and NSC61610 that bind to LANCL2 have been developed 
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as potential, pharmaceutical activators of the LANCL2 pathway. 
BT-11 is being developed as a first-in-class oral small molecule 
therapeutic for Crohn’s disease (74, 75). BT-11 is an orally 
active, locally acting small molecule compound that binds 
to LANCL2 in the gastrointestinal (GI) tract and decreases 
leukocytic infiltration, mucosal thickening, and epithelial ero-
sion in the GI tract. These histological improvements correlate 
with decreased numbers of inflammatory F4/80+CD11b+ mac-
rophages and effector T helper 1 (Th1) cells in the gut mucosa. 
BT-11 also increases the levels of FOXP3-expressing CD4+ Treg 
that express IL-10 in the gut lamina propria, spleen, and MLN. 
Gene expression analyses confirmed that oral administration of 
BT-11 upregulates the expression of IL-10 and LANCL2, and 
downregulates the expression of TNFα GI tissue of mice with 
experimental IBD. Furthermore, PK studies with BT-11 showed 
low plasma concentrations and elimination within hours after 
oral administration. Plasma concentrations were only slightly 
higher after oral administration of 500  mg/kg than they were 
after 80 mg/kg (sixfold dose difference). BT-11 concentrations 
in the intestine after the 80 mg/kg treatment were considerably 
higher than concentrations measured in plasma at the same 
time. In addition, BT-11 gave consistent 90% IBD reduction in 
three mouse models after both oral and rectal administration 
(8 mg/kg).
Membrane Localization of LANCL2 and 
Mechanism of ABA Transport through  
the Plasma Membrane
Lanthionine synthetase C-like 2 anchoring to the plasmamem-
brane occurs via N-terminal myristoylation and also via a basic 
phosphatidylinositol phosphate-binding site (28). LANCL2 is 
not a transmembrane protein, as it is detached from the eryth-
rocyte membrane by relatively mild chemical treatments, in the 
absence of detergents (77). Thus, LANCL2 localization implies 
that ABA binding may occur intracellularly, raising the issue of 
how ABA gains access to its intracellular receptor. Protonated 
ABA can diffuse through the lipid bilayer and this passive dif-
fusion is believed to drive ABA out of the xylem sap and into 
plant cell tissues, although transmembrane, ATP-dependent 
ABA transporters are also present in plant cells (78). The pKa 
of ABA is 4.7; thus at pH values typical of extra- and intracel-
lular fluids in animals (approximately 7.5) <0.2% of ABA is 
protonated and ABA is mostly membrane impermeable. The 
protein responsible for ABA transport was identified as the 
anion transporter Band 3 in human erythrocytes (RBC), on 
the basis of several lines of evidence: (i) chloride ions compete 
with ABA for influx into RBC; (ii) the specific Band 3 inhibitor 
DIDS inhibits influx of ABA; (iii) Band 3 binds bio-ABA and 
bio-ABA can be displaced by excess ABA, indicating a specific 
interaction between ABA and the transporter; (iv) proteoli-
posomes reconstituted with purified Band 3 are able to transport 
ABA and sulfate (77). The erythrocyte anion transporter Band 
3 (also called AE1) is a member of a protein family of anion 
transporters that includes AE2 and AE3. While AE1 is expressed 
only on erythrocytes, AE2 and AE3 are expressed in nucleated 
cells. In line with what was observed on Band 3, AE2 has been 
recently shown to mediate ABA transport in human nucleated 
cells and to allow the functional effect of extracellular ABA in 
keratinocytes (79).
ABA transport across AE1 and AE2 is bidirectional, allow-
ing the free flux of ABA along its concentration gradient. The 
non-concentrative nature of the transporter allows circulating or 
paracrinally produced ABA to exert its functional effect on target 
cells: ABA-releasing cells can export ABA to bystander cells or 
into the bloodstream and ABAp can reach cells distant from the 
ABA-producing ones. Indeed, autocrine (9–11, 16, 17), paracrine 
(12, 15–17), and endocrine (13, 40, 55) effects of ABA have been 
described.
ABA/LANCL2 Signaling in Cells involved  
in Glucose Homeostasis: Adipocytes, 
Myocytes, and Hepatocytes
The first evidence indicating that ABA, similar to insulin, trig-
gers the Ser phosphorylation of protein kinase Akt, came from 
experiments on adipocytes, as already described above (9). Later, 
by the use of LY294002, a PI3K specific inhibitor, the PI3K/Akt 
signaling pathway was demonstrated to mediate the ABA-
induced activation of NADPH oxidase and of ROS generation, in 
the murine macrophage cell line RAW264.7 (11) and of glucose 
transport in rodent 3T3-L1 adipocytes (80). More recently, Zeng 
et al. (62) demonstrated that LANCL2 positively regulates Akt 
phosphorylation in four different liver cell lines. This regulation 
does not occur through the canonical-insulin signaling pathway, 
since LANCL2 knockdown affected neither the level of insulin 
receptor nor its phosphorylation. Instead, LANCL2 was found 
to physically interact with Akt. Through in  vitro kinase assays 
with immunoprecipitated mTORC2 (one of the kinases hav-
ing Akt as substrate) and recombinant Akt, in the absence or 
presence of purified LANCL2, Zeng et  al. (62) demonstrated 
that LANCL2 regulates Akt phosphorylation by mTORC2. In 
addition, LANCL2 facilitates the phosphorylation of SGK1, and 
in turn of NDRG1, by mTORC2. Whether LANCL2 physically 
interacts with SGK1, as a common mechanism with Akt, in 
order to facilitate its phosphorylation by mTORC2, remains to 
be determined. Given the established role of ABA and of Akt 
in glycemia regulation, further investigation on the molecular 
interaction between LANCL2 and Akt in cells other than liver 
cells are needed.
ABA/LANCL2 Signaling in immune 
Modulation
ABA expands human uncommitted HP in  vitro: 24-h priming 
with low micromolar ABA prior to seeding of the cells in a growth 
factor-enriched medium stimulates colony output from human 
cord blood-derived colony forming cells (CFC) and also from 
purified CD34+ cells, the subpopulation of HP containing the 
most immature progenitor cells. ABA stimulates the proliferative 
potential of the single CFC, increasing cell number in first genera-
tion colonies, and also stimulates the self-renewal of clonogenic 
HP, increasing the number of second and third generation colo-
nies and resulting in a 1-log higher cell expansion factor in the 
ABA-treated cells compared with controls (15).
FiGURe 3 | Schematic representation of immune modulatory actions of ABA in mesenchymal stem cell (MSC), CD34+ cells, T cells, and macrophages through 
lanthionine synthetase C-like 2 (LANCL2)-dependent mechanisms.
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The stimulatory effect of ABA on HP proliferation is mediated 
by an increase of the Cacyt
2+, which is dependent upon a signaling 
pathway sequentially involving a PTX-sensitive Gi, stimulation 
of the ADPRC activity of CD38 and increase of intracellular 
cADPR (15). The ABA-induced increase of the Cacyt
2+ exerts 
transcriptional effects on HP via the nuclear translocation of 
NF-kB, stimulating transcription and release of several cytokines 
and growth factors, including VEGF, IL-8, IL-1β, IL-9, Fas ligand, 
GRO, and RANTES. VEGF and IL-8 are partly responsible for 
the autocrine stimulation of cell proliferation induced by ABA 
on HP, since blocking antibodies against these cytokines reduce 
the ABA-mediated increase of colony output. Interestingly, IL-8 
stimulates release of ABA from MSCs (14).
In the hemopoietic niche, MSCs provide physical and trophic 
support to HP, and function as immunomodulators, preventing 
lymphocyte activation, which negatively affects hemopoiesis. 
Indeed, MSC co-transplantation is a routine practice in allogeneic 
hematopoietic stem cell transplantation in some hematological 
centers (81). Several cytokines released by activated allogeneic 
lymphocytes, TNF-α, RANTES, and IL-8, induce the release of 
ABA from human MSCs; ABA in turn stimulates MSC prolif-
eration and the release of hemopoietic growth factors, including 
IL-6, IL-8, oncostatin M, MIP-1d, and GRO (14). Presence of an 
anti-ABA monoclonal antibody prevents the growth-stimulatory 
effect of the coculture with MSC on second generation colony out-
put from CD34+ cells (15). Thus, a positive feedback mechanism 
can be envisioned between MSC and HP in the hemopoietic 
niche, where ABA released by MSC behaves as an autocrine 
stimulator of stromal function and as a paracrine growth factor 
for HP (Figure 3).
ABA is also released by activated granulocytes (see Figure 1), 
eliciting the intriguing hypothesis that ABA may function as 
either a “danger” signal during infection or inflammation or a 
regulatory molecule for maintaining immune homeostasis. Such 
series of events are intimately linked to activation of LANCL2, 
which triggers a decrease in F4/80+CD11b+ macrophages, plus 
an increase in circulating Treg cells after dietary ABA treatment 
(65). The activation of LANCL2 also triggers a release of IL-10 
in CXCR3+ macrophages (Figure  3). Linked to these findings, 
Bassaganya-Riera et  al. (34) published a study demonstrating 
that dietary ABA supplementation reduced levels of TNFα while 
upregulating Glut4 in the spleen during LPS challenge of mice. 
These results have been validated by another study in which 
activation of LANCL2 led to a decrease in TNFα, MCP-1, and 
IFNγ, as well as a reduction in Th1 CD4+ T cells and an increase in 
Treg cells by the novel LANCL2 ligand, BT-11 (75). BT-11 binds 
to LANCL2, is orally active, has demonstrated efficacy in three 
validated mouse models of IBD at 8  mg/kg, and has a benign 
safety profile based on single dose, multiple dose and DRF studies 
in rats up to 1,000 mg/kg (74). Thus, activation of LANCL2 acts 
as an internal sensor activated by environmental dysregulation 
(e.g., inflammatory, dietary, or metabolic signals) that activates 
10
Zocchi et al. Health Benefits of ABA
Frontiers in Nutrition | www.frontiersin.org June 2017 | Volume 4 | Article 24
cellular and molecular pathways involved in homeostatic control 
of immunity and metabolism.
CONCLUSiON
ABA and its proposed receptor LANCL2 are emerging as new 
important players in the physiology and in the dysfunction of 
mammalian glucose homeostasis and immunoregulation. Over 
28.3 million Americans have T2D and over 40.1% of middle-aged 
adults have prediabetes, a disease that has reached pandemic 
proportions in the U.S. Diabetes is the seventh leading cause of 
death worldwide, mainly due to its cardiovascular sequel. While 
T2D is an irreversible condition, prediabetes is not. Only less 
than 4% of prediabetic subjects receive pharmacologic treatment, 
as they do not yet classify as “diabetic.” Prediabetic or high-risk 
individuals, such as those afflicted by excess body weight, high 
blood lipids and hypertension, all hallmarks of the metabolic 
syndrome, are advised to follow dietary and lifestyle guidelines, 
which have a very low rate of adherence. Consequently, many of 
these subjects will become diabetic. This dramatic forecast calls 
for new and aggressive strategies to tackle the expanding inci-
dence of diabetes pandemic before it becomes an even greater 
societal burden.
Dietary low-dose ABA improves glucose tolerance in healthy 
subjects without increasing insulinemia and oral ABA improves 
glucose tolerance in diabetic mice. Furthermore, the increase of 
ABAp that occurs after an OGTT is impaired in patients with 
T2D and in women with GDM. The mechanism of action of 
low-dose ABA in  vivo is likely mediated by its stimulation of 
GLUT4-mediated glucose uptake, rather than insulin release, as 
insulinemia is in fact reduced by ABA treatment. Dietary ABA 
administration in the form of foods or beverages can be proposed 
as a new intervention, capable of improving glucose tolerance, 
while at the same time sparing the β-cell reservoir. ABA is both 
an endogenous and dietary LANCL2-activating compound. 
Nanomolar plasma concentrations, in the physiological range 
and attainable by dietary intake of a dose of approximately 1 µg/kg 
body weight, are effective on glycemic control. These two facts 
together allow its safe use to maintain healthy blood glucose 
levels and to prevent diabetes. In addition, low-dose ABA does 
not increase insulin release and this may prove advantageous in 
diabetic, prediabetic, and metabolic syndrome subjects, who are 
deficient in and/or resistant to insulin. By reducing the chronic 
stimulation by hyperglycemia of β-cells to release insulin, low-
dose ABA administration should improve survival and function 
of these cells.
Identifying other LANCL2-activating compounds may also 
prove a successful strategy, in view of the multiple anti-diabetic, 
anti-inflammatory, and immunoregulatory effects that they 
might trigger. Indeed, LANCL2 can: (i) facilitate Akt phos-
phorylation and increase GLUT4-mediated glucose uptake, an 
Akt-dependent mechanism; (ii) mediate the ABA-stimulated 
GLP-1 release from L cells; and (ii) exert immunoregulatory and 
anti-inflammatory actions in the gut, blood vessels, and adipose 
tissue. The potential role of LANCL2 as a new drug target in 
diabetes has already been suggested (82) and efforts at discov-
ering LANCL2-targeting drugs are underway. Furthermore, 
the ABA-based technology through the LANCL2 pathway to 
fight inflammation and diabetes has been patented, through 
method of utilization as well as composition of matter claims, by 
Bassaganya-Riera et al.
In summary, the data reviewed in this manuscript demon-
strates that dietary or endogenously produced ABA is a new 
human signaling molecule that regulates responses to environ-
mental challenges (i.e., metabolic, nutritional, inflammatory, and 
immunological), and it is implicated in glycemic control through 
a LANCL2-dependent mechanism. ABA not only regulates blood 
glucose levels and prevents the onset of T2D in mice and rats, 
but more importantly microgram amounts of dietary ABA are 
sufficient to improve glycemic controls in humans. Given the 
extensive results demonstrating a role for ABA in regulating 
glycemic control, ABA-based interventions have the potential 
to improve glycemic control in millions of people afflicted by 
prediabetes, diabetes, and metabolic syndrome worldwide.
MeTHODS
This comprehensive and up-to-date review summarizes the 
in  vitro, preclinical, mechanistic, and clinical results obtained 
over the past 15 years by the two leading groups involved in the 
study of the metabolic, nutritional, and immunological actions of 
ABA. Only two such reviews exist on this subject (83, 84); with 
the new review, the authors wish to implement the literature with 
their most recent results, focusing on the arguably most clinically 
relevant role of ABA as a new human hormone involved in the 
control of glycemia. The authors kept a balance between indepen-
dently published papers and papers published by the authors. The 
scientific literature summarized in the review has been published 
over the years 2001–2017 in peer-reviewed international journals, 
including Proc Natl Acad Sci U S A, J Biol Chem, FASEB J, Stem 
Cells, Clin Nutr, J Nutr Biochem, J Cell Physiol, and PloS One, 
among others.
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